Abstract
Topical microbicides that reduce or eliminate the risk of human immunodeficiency virus type 1 (HIV-1) sexual transmission must function effectively within the cervicovaginal environment where multiple factors may impact the efficacy of the active agent. Factors relevant to potential changes in microbicide efficacy include the presence of mucins within the cervical mucus. We hypothesize that polycationic PEHMB molecules will interact with the anionic mucin molecules to form a lattice-like network that serves as a physical barrier to the movement of infectious virus and HIV-1-infected cells to the cervical and vaginal epithelia. In vitro experiments demonstrated that the anti-HIV-1 activity of PEHMB was increased almost two logs in the presence of mucin. In contrast, the activity of anionic dextran sulfate was unaffected. These results suggest that electrostatic interactions between PEHMB and mucin molecules may augment the inherent antiHIV-1 activity of PEHMB by facilitating the formation of a physical barrier between HIV-1 and susceptible cells. This property would be expected to increase the in vivo efficacy of PEHMB. from 2005 International Meeting of The Institute of Human Virology Baltimore, USA, 29 August – 2 September 2005
Highlights
The Presence of Mucin Increases the Anti-human immunodeficiency virus type 1 (HIV-1) Activity of the Candidate Microbicide Polyethylene Hexamethylene Biguanide (PEHMB)
national Meeting of The Institute of Human Virology Meeting abstracts – A single PDF containing all abstracts in this Supplement is available here. [link 'here' using 'a href' to: http://www.biomedcentral.com/content/pdf/1742-4690-2-S1
Topical microbicides that reduce or eliminate the risk of human immunodeficiency virus type 1 (HIV-1) sexual transmission must function effectively within the cervicovaginal environment where multiple factors may impact the efficacy of the active agent
Summary
The Presence of Mucin Increases the Anti-HIV-1 Activity of the Candidate Microbicide Polyethylene Hexamethylene Biguanide (PEHMB). Vanessa Pirrone*‡1, Shendra Miller1, Mary L Ferguson1, Lori Schlipf1, Mohamed E Labib2, Robert F Rando2, Brian Wigdahl1 and Fred C Krebs1 Address: 1Department of Microbiology and Immunology, and Institute for Molecular Medicine and Infectious Disease, Drexel University College of Medicine, Philadelphia, PA, USA and 2Novaflux Biosciences, Inc., Princeton, NJ, USA
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have